Parkinson's disease

GLP-1 Receptor Agonists and Brain Neuroprotection

In 2021, researchers at Lund University began testing exenatide, a GLP-1 receptor agonist, for potential neuroprotection in Parkinson's disease—a use far removed from its original approval for type 2 diabetes.